"Obesity is a chronic disease, just like diabetes, high blood pressure and high cholesterol," Aronne said
The most effective GLP-1 drug for weight loss currently (as of early 2026) is tirzepatide, marketed under the names Zepbound (for weight loss) and Mounjaro (for diabetes)
Metformin targets insulin resistance and liver glucose output, while semaglutide adds incretin-based effects and appetite support
In a 2020 meta-analysis of seven CVOTs, the use of GLP-1RAs was associated with a 15% lower risk of non-fatal stroke, a 19% lower risk of fatal stroke, and a 16% lower risk of total stroke [2]
If you have been on 10 units (0.5 mg from a 5 mg/mL vial) for four weeks and feel no difference in appetite, discuss with your provider whether escalation is appropriate